Search This Blog

Monday, June 1, 2026

Greenwich LifeSciences Phase III: significant GLSI-100 immune responses in non-HLA-A*02 breast cancer

 

Greenwich LifeSciences Phase III FLAMINGO-01 data show significant GLSI-100 immune responses in non-HLA-A*02 breast cancer patients at ASCO 2026

  • Company says 2025 Form 10-K is in final approval and Phase III payable review adjustments are not material.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)